News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Concludes Enrollment for the Phase III Study of StemEx┬«, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma



2/13/2012 6:13:57 AM

JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma, who cannot find a family related, matched bone marrow donor.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Lymphoma
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES